Elkrief, Arielle http://orcid.org/0000-0003-1981-1535
Méndez-Salazar, Eder Orlando
Maillou, Jade http://orcid.org/0009-0008-2475-9931
Vanderbilt, Chad M.
Gogia, Pooja
Desilets, Antoine http://orcid.org/0000-0002-9382-7597
Messaoudene, Meriem
Kelly, Daniel
Ladanyi, Marc
Hellmann, Matthew D.
Zitvogel, Laurence
Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
Routy, Bertrand http://orcid.org/0000-0003-1955-9149
Derosa, Lisa
Schoenfeld, Adam J.
Article History
Received: 20 September 2023
Accepted: 13 June 2024
First Online: 16 July 2024
Competing interests
: AJS reports consulting/advising role to J&J, KSQ therapeutics, BMS, Merck, Enara Bio, Perceptive Advisors, Oppenheimer and Co, Umoja Biopharma, Legend Biotech, Iovance Biotherapeutics, Obsidian Therapeutics, Prelude Therapeutics, Immunocore, Lyell Immunopharma, Amgen and Heat Biologics. Research funding: GSK (Inst), PACT pharma (Inst), Iovance Biotherapeutics (Inst), Achilles therapeutics (Inst), Merck (Inst), BMS (Inst), Harpoon Therapeutics (Inst), AffiniT therapeutics (Inst), Legend Therapeutics (Inst), and Amgen (Inst). M.D.H. receives research funding from Bristol-Myers Squibb; is paid consultant to Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Janssen, Nektar, Syndax, Mirati, and Shattuck Labs; receives travel support/honoraria from AstraZeneca and BMS; and a patent has been filed by MSK related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx. Subsequent to the completion of this work, M.D.H. began as an employee (and equity holder) at AstraZeneca. C.M.R. has consulted with AbbVie, Amgen, Astra Zeneca, D2G, Daiichi Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz, Kowa, Lilly, Merck, and Syros. He serves on the scientific advisory boards of Auron, Bridge Medicines, Earli, and Harpoon Therapeutics. B.R. reports honorarium for Merck, BMS and AstraZeneca as well as research funding with Davolterra and Kanvas. LD reports honorarium for BMS and AstraZeneca. L.Z. is founder of everImmune and its SAB President. L.D. is an everImmune SAB member. L.Z. received a research contract from Kaleido, 9 meters/Innovate Pharma and is currently sponsored by Pileje.